Johnson & Johnson (JNJ) News
Filter JNJ News Items
JNJ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JNJ News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest JNJ News From Around the Web
Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
Cramer on Johnson & Johnson (JNJ): A Value Trap Amid Lawsuits and SetbacksWe recently published a list of Jim Cramer Discussed These 29 Stocks Ahead Of Major AI Event. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other stocks ahead of major AI event that Jim Cramer discussed. In his appearance on Squawk on the Street the […] |
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. |
FDA Accepts J&J's Filing for Autoimmune Disease Drug NipocalimabJNJ's filing seeks the FDA's approval for nipocalimab to treat generalized myasthenia gravis in a broad population of antibody-positive patients. |
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to AvoidAmong the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry. |
Contineum concludes enrolment in Phase II multiple sclerosis therapy trialThe trial is evaluating the efficacy and safety of PIPE-307 in RRMS patients. |
How to Find Strong Medical Stocks Slated for Positive Earnings SurprisesWhy investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
J&J Pauses Sales of Atrial Fibrillation Device, Stock DownJ&J's MedTech unit pauses all cases of the Varipulse PFA system as part of an external evaluation. Stock dips. |
Nipocalimab granted U.S. FDA Priority Review for the treatment of generalized myasthenia gravisJohnson & Johnson (NYSE: JNJ) today announced the nipocalimab Biologics License Application (BLA) received Priority Review designation from the U.S Food and Drug Administration (FDA) for the treatment of antibody positive (anti-AChR, anti-MuSK, anti-LRP4) patients with generalized myasthenia gravis (gMG), as supported by findings from the Phase 3 Vivacity-MG3 study. The FDA grants Priority Review to applications for medicines that, if approved, would offer significant improvements in the safety |
Johnson & Johnson MedTech pauses Varipulse rollout in USDespite the pause, the company clarified that the suspension does not impact commercial activity outside the US. |
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key ProductJohnson & Johnson stock skidded Wednesday after the company temporarily paused sales of its pulsed field ablation system. |